Ralph Passarella is a Co-founder of Care Access, a global clinical research company focused on making clinical trials more accessible for communities; and, faster and more predictable for life science companies. Ralph is also the Co-founder and CEO of Reify Health and Co-founder of Signal Vine, an education technology company that was spun out of Reify Health and is focused on helping students navigate the administrative parts of higher education.

Mike Franklin is Vice President of Community Based Research at Eli Lilly and Company. In his role, he is responsible for the delivery of a global strategy to bring research, awareness, and accessibility of clinical trials into the communities that these medicines will ultimately serve. Mike has over 30 years of drug development experience across the pharmaceutical & research industry.

Gaurav Agrawal is a Senior Partner in McKinsey’s Life Sciences Practice, where he advises biotechnology, pharmaceutical, vaccine companies, global health institutions, and public sector organizations on innovation, R&D productivity, and growth. With more than 15 years of experience spanning therapeutics and vaccines, he helps clients design new innovation models, enhance clinical trial strategies, and accelerate the delivery of transformative therapies to patients.

He co-leads McKinsey’s global work in product development excellence, with a focus on advancing biopharma asset development and improving performance through patient-centric approaches and data-driven insights. Gaurav has guided leading pharmaceutical companies through major R&D transformations, supported public health organizations with funding strategies, and helped launch and scale biotech startups.

His expertise also extends to vaccines and global health, where he has advised private sector, philanthropic, and public health institutions on strategy and adoption. He led McKinsey’s R&D response during the Ebola epidemic and chaired the firm’s global COVID-19 taskforce, supporting clients on vaccine and therapeutic development and pandemic recovery.

Gaurav holds an MBA from Harvard Business School and a BTech in Mechanical Engineering from the Indian Institute of Technology.

Kendra Taylor is currently a Clinical Trial Solutions Lead at Pfizer. She has been partnership lead within Clinical Development & Operations for community-based site networks and retail pharmacies. Her role involves driving strategy development from due diligence to implementing of various types of capabilities and solutions for clinical trials. Kendra brings over two decades of experience across clinical research, strategic innovation, and business development. Kendra holds a Doctorate in Biology from the University of South Carolina and a master's degree from Harvard Medical School, Master of Medical Science (MMSc). Kendra trained in Immunology and was an Instructor in Medicine at Harvard’s teaching hospitals: Brigham and Women’s Hospital and Massachusetts General Hospital-Cancer Center, Boston, MA.

Joyce is the Director of Combination Product Device Development at Takeda Pharmaceuticals. She has two decades of experience spanning device development, manufacturing, and post-market lifecycle management. Her expertise includes a wide range of platforms such as autoinjectors, pen injectors, dual-chamber cartridges and injectors, prefilled syringes, and large-volume wearable/on-body delivery systems.

In addition to her leadership in device development, Joyce is an expert in in-silico modeling and simulation, with a focus on combination product performance prediction and optimization. Her work has advanced the integration of computational methods into the end to end combination product device development pathways. Before joining Takeda, Joyce spent nine years with Becton Dickinson (BD) and two years with Dr. Reddy’s Laboratories, where she held multiple roles in drug delivery device development. These positions allowed her to gain hands-on experience across the full product lifecycle, from early-stage design, commercial readiness through post-launch lifecycle management.

Joyce holds a PhD and MS in Mechanical Engineering, as well as a BS in Materials Science and Engineering

As the Managing Director - Digital Therapeutics at Medidata, Josh Brouillette is at the helm of an exciting new frontier for patient care. For 15 years, Josh has been a driving force in the Pharma and Biotech sectors, consistently working to advance therapeutic access through the strategic application of technology platforms. Having recently rejoined Medidata, he is now leading the charge to integrate Digital Therapeutics into clinical development, specifically through a groundbreaking partnership with Click Therapeutics, ultimately ensuring innovative, life-saving solutions reach patients faster.

Cathleen Bergin has been in the biotech industry 20 plus years with extensive experience in building and evolving patient support program strategy and support for patients,  as well as leading clinical educator field teams to meet both HCPs and patient’s educational needs. 

She has extensive launch experience in the rare disease markets of hematology, nephrology and neurology which include all formulation of therapy including large volume sub cutaneous injection.

Cathleen is presently responsible for leading a US field Clinical Educator Team which is responsible for the education of Sites of Care, HCPs and patients around dosing and administration of all indications and formulations for the neurology/neuromuscular community. 

Prior to argenx, Cathleen has worked in multiple positions on the commercial side of rare disease with increasing responsibility. 

She practiced as a Nurse Practitioner before entering the rare disease market with clinical expertise in Hematology, Oncology, Transplant and Neurology.

As a person living with multiple myeloma since 2017 and an active patient and research advocate, Todd strives to leverage his lived experience as a cancer patient with his 30+ years of professional experience in the pharmaceutical industry, to advance patient-centered cancer research, education, empowerment and access.  He is a support group leader, cancer coach, author, and advisor on numerous research collaboratives and clinical trials. He believes that early and ongoing integration of patient and care partner perspectives is essential for strategic success and optimal outcomes.

Liat Shochat is Vice-President of Combination Product Development and has over 20 years of experience in design and development management of combination products and medical devices. Her expertise includes strategic and technical development, lifecycle management and global launch of various single-use, disposable electro-mechanical drug delivery platforms, drug-device combination products and medical devices.

Throughout her career, Ms Shochat has held management roles in R&D, engineering, project management, regulatory, human factors and clinical trials.

Steven Lee is the Director of Strategy at Click Therapeutics, where he is at the forefront of the future of digital therapeutics and drug+software combination products. With over a decade of advisory experience in the Pharma and BioTech industries, he brings focused expertise in market access and commercialization of innovative treatment solutions. Prior to Click, Steven led strategic advisory teams that helped solve commercialization challenges for leading pharmaceutical manufacturers.

Andrew Schaefer is a Program Manager at Congruence Medical Solution, LLC. He is passionate about solving unmet, emerging and hard-to-solve problems in drug delivery. He responsible for the development of novel devices, including devices for implantation of solid drug depots. Andrew is a mechanical engineer by training.